A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis. OMERACT Drug Safety Working Party.
This paper proposes the creation of an objectively acquired reference database to more accurately characterize the incidence and longterm risk of relatively infrequent, but serious, adverse events. Such a database would be maintained longitudinally to provide for ongoing comparison with new rheumatologic drug safety databases collecting the occurrences and treatments of rare events. We propose the establishment of product-specific registries to prospectively follow a cohort of patients with rheumatoid arthritis (RA) who receive newly approved therapies. In addition, a database is required of a much larger cohort of RA patients treated with multiple second line agents of sufficient size to enable case-controlled determinations of the relative incidence of rare but serious events in the treated (registry) versus the larger disease population. The number of patients necessary for agent-specific registries and a larger patient population adequate to supply a matched case-control cohort will depend upon estimates of the detectability of an increased incidence over background. We suggest a system to carry out this proposal that will involve an umbrella organization, responsible for establishment of this large patient cohort, envisioned to be drawn from around the world.
Lipani
J A
JA
Department of Medicine, Standford Universiity, Palo Alto, CA, USA.
Strand
V
V
Johnson
K
K
Woodworth
T
T
Furst
D
D
Singh
G
G
Day
R
R
Brooks
P
P
D016907:Adverse Drug Reaction Reporting Systems / Q000458:organization & administration*; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000633:toxicity*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000592:standards; D015331:Cohort Studies; D006801:Humans; D012042:Registries
D018501:Antirheumatic Agents